Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis (Phase II Pilot Study, Multicentre, International, Randomised, Double-masked, Placebo-controlled, 2x40 Patients).

Next Previous
Trial Profile

Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis (Phase II Pilot Study, Multicentre, International, Randomised, Double-masked, Placebo-controlled, 2x40 Patients).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2013

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ganciclovir (Primary)
  • Indications Keratoconjunctivitis
  • Focus Therapeutic Use
  • Sponsors Laboratoires Thea

Most Recent Events

  • 28 Apr 2012 Additional trial location (Germany) identified as reported by European Clinical Trials Database.
  • 28 Apr 2012 Planned number of patients changed to 80 as reported by European Clinical Trials Database.
  • 28 Apr 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2007-002455-16).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top